BridgeBio Oncology Therapeutics (BBOT) SEC Filings: History & Chart

BridgeBio Oncology Therapeutics Inc.(BBOT)

Biotechnology · South San Francisco, CA

$3.54-0.06 (-1.67%)

Delayed quote: Oct 6, 2026, 10:19 AM EDT

About BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

South San Francisco, CA

88 employees

bbotx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pedro J. Beltran

View full financials

Form	Filing Date	Accepted	Document
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Sep 14, 2026	Sep 14, 2026	View filing
EFFECT	Sep 10, 2026	Sep 11, 2026	View filing
EFFECT	Sep 8, 2026	Sep 9, 2026	View filing
8-K	Sep 8, 2026	Sep 8, 2026	View filing
S-3	Sep 1, 2026	Sep 1, 2026	View filing
POS AM	Sep 1, 2026	Sep 1, 2026	View filing
424B3	Aug 12, 2026	Aug 11, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
SC 13D/A	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
424B3	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
424B3	May 13, 2026	May 13, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing

SEC Filings

Recent Filings